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Overthe past twodecades, Candida species have come to be regarded as impor-
tant agents ofnosocomial infection. In this paper, initially presented as a teach-
ing conference at theYale University School ofMedicine, we summarize recent
information pertaining to the epidemiology, diagnosis, and treatment of sys-
temic Candida infections.
INTRODUCTION
The past two decades have witnessed a significant change in the epidemiology of
nosocomial infections in the United States. Increasing rates of invasive procedures, bone
marrow and solid organ transplantation, and use ofimmunosuppressive agents and broad-
spectrum antibiotics have resulted in an increasingly large population ofpatients with high
susceptibility to nosocomial infections. Of note, the rate of fungal infections, primarily
caused by Candida species, has risen significantly since the early 1980s [1]. These infec-
tions are often difficult to diagnose and treat and carry a high burden of morbidity and
mortality. We discuss the recent literature pertaining to the changing epidemiology ofsys-
temic Candida infections in the United States, new diagnostic tests, available antifungal
agents, and currently recommended treatment, with an emphasis on candidemia and deep
Candida infections rather than mucocutaneous manifestations ofcandidiasis.
EPIDEMIOLOGY
Importance ofCandida spp. as nosocomialpathogens
Candida species are the pathogens in an increasing proportion of nosocomial blood-
stream infections in the United States. This increase has been noted in hospitals of all
sizes, but is particularly striking in large tertiary care institutions. Much ofthe data docu-
menting this has been collected by the National Nosocomial Infections Surveillance
System (NNIS)b. This cooperative group of over 100 U.S. hospitals conducts prospective
surveillance on nosocomial infections [2]. The participating hospitals are ofvarying sizes
and include both teaching and non-teaching facilities. A uniform definition of nosocomi-
al infection [3] is employed and all such infections were reported to the Centers for
Disease Control and Prevention.
The data collected by the NNIS have been analyzed in a number of ways and at sev-
eral timepoints. All of these analyses indicate an increase in the frequency of fungi as
agents ofnosocomial infection, with Candida spp. being by far the most common agents.
Considering all major sites of infection, the proportion of nosocomial infections reported
secondary to fungi in 115 ofthe NNIS hospitals rose from 6.0 percent in 1980 to 10.4 per-
aTo whom allcorrespondence shouldbe addressed: VincentT. Andriole, M.D., Section ofInfectious
Diseases, Yale University School of Mecicine, 333 Cedar St., New Haven, CT 06520-8056, Tel.:
203-785-4141; Fax: 203 785 6179; E-mail: andriolevt@maspo3.mas.yale.edu.
bAbbreviations: NNIS, National Nosocomial Infections Surveillance System; 5-FU, 5-fluorouracil;
5-FC, 5-fluorocytosine; cfu, colony-forming units.
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cent in 1990 [1]. The overall rate of nosocomial infections secondary to fungi rose from
2.0 to 3.8 infections per 1,000 patient discharges during this period. By site, the largest
increases were noted in surgical wound infections (an increase from 1.0 to 3.1 per 10,000
patient discharges), urinary tract infections (9.0 to 20.5 per 10,000 patient discharges) and
bloodstream infections (1.0 to 4.5 per 10,000 patient discharges). The majority (78 per-
cent) of these infections were secondary to Candida species, predominantly C. albicans
(approximately 59 percent).
Another study [4] analyzed NNIS data between 1980-1989 to estimate changes in
both the rates and microbiology ofnosocomially-acquired primary bloodstream infections
in 124 hospitals. Hospitals were stratified by size and teaching affiliation. Significant
increases in the overall nosocomial bloodstream infection rate were noted in all hospitals
studied and ranged from an increase of 279 percent in small nonteaching hospitals to 70
percent in large teaching hospitals. The largest rate increases were noted for four groups
ofpathogens: coagulase-negative Staphylococci, Staphylococcus aureus, Enterococci, and
Candida spp. For Candida, the bloodstream infection rate increased the most in large
teaching hospitals (1.61 per 1,000 hospital discharges in 1989, representing a 487 percent
increase over 1980).
Candida spp. have supplanted gram-negative rods in terms of frequency of isolation
in nosocomial infections (Table 1, [5]). In 1984, Candida were the eighth most common
pathogen isolated, behind coagulase-negative Staphylococci, S. aureus, and several
species ofgram-negative rods. By 1988, Candida spp. rose in frequency to the fourth most
common pathogen isolated, surpassing all of the above gram-negative rods.
A recently published twelve-year retrospective study of nosocomial bloodstream
infections in a single large tertiary care institution [6] revealed data similar to that obtained
by the NNIS. An overall increase in the crude nosocomial infection rate was noted, from
6.7 per 1000 discharges in 1980 to 18.4 per 1000 discharges in 1992. The bulk of this
increase was secondary to increases in the rates of Staphylococci, Enterococci, and
Candida spp. The rate of Candida bloodstream infection increased twelve-fold during this
period.
Table 1: Relative frequencies ofbloodstream infection pathogens, 1988 vs. 1984.
Pathogen Percent of bloodstream Rank in 1988 Rank in 1984
infections, 1988
Coagulase-negative
Staphylococci 25.5 1 1
S. aureus 15.0 2 2
Enterococci 7.9 3 6
Candida spp. 7.8 4 8
E. coli 6.8 5 3
Enterobacter spp. 5.2 6 7
P aeruginosa 5.0 7 5
Klebsiella spp. 4.4 8 4
From: Horan et al, [5].
Mortality and riskfactors
Candidemia and deep Candida infections are associated with a high mortality rate.
Most series document a crude mortality rate ofsixty to eighty percent [7-9]. The patients
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represented in these studies are generally quite ill and have at least one serious comorbid
condition (such as leukemia, lymphoma, other malignancy, bacterial sepsis, complicated
post-operative course). These underlying conditions could in themselves contribute to a
substantial proportion ofmortality. One retrospective case-control study [8] attempted to
determine the excess mortality attributable to candidemia. In this study 88 candidemic
patients were matched with 88 control patients on the basis of age, sex, time in hospital,
underlying illness, and major surgical procedure. The crude mortality rate for the candi-
demic patients was 57 percent, compared with 19 percent for the control patients, with a
calculated attributable mortality of 38 percent. Thus, candidemia appears to be responsi-
ble for considerable mortality, even after controlling for underlying comorbid illness.
Another recent series of 106 medical and surgical patients [9] with candidemia in a
tertiary care hospital attempted to determine host and iatrogenic factors associated with
serious Candida infections as well as factors predictive ofincreased mortality. Common
factors among the patients revealed the presence of a central venous catheter in 85 per-
cent, use ofparenteral hyperalimentation in 61 percent, and prior antibiotic use in 94 per-
cent (62 percent receiving 4 or more antibiotics). Neutropenia was also a common risk
factor (29 percent). Patients with sustained candidemia, defined by the authors as positive
blood cultures ofgreater than two days duration, were significantly more likely to die than
were those with shorter duration of positive blood cultures (mortality rates of 74 percent
vs. 39 percent). Use ofcentral venous catheters, parenteral nutrition, and neutropenia were
significantly associated with sustained candidemia.Also, among those with sustained can-
didemia, infection with a non-albicans species was associated with ahighermortality rate,
whereas absence of a malignancy or fatal underlying illness was associated with a lower
mortality rate.
PATHOGENESIS
Candida consist ofapproximately 150 species ofoval budding yeasts which are ubiq-
uitous in the environment. Of these, only about 10 species are common pathogens in
humans [10]: C. albicans, C. glabrata (formerly Torulopsis glabrata), C. guilliermondii,
C. parapsilosis, C. tropicalis, C. pseudotropicalis, C. lusitaniae, C. krusei, C. stellatoidea,
and C. rugosa. C. stellatoidea is now considered a variant of C. albicans.
C. albicans is the most common pathogen, accounting for roughly sixty to seventy-
five percent of Candida isolates in most series [1, 6, 8]. There is some evidence, howev-
er, that this is changing with changing patterns ofantifungal administration. In particular,
the extensive use of fluconazole appears to select for certain non-albicans species. One
institution [11] noted a shift from C. albicans as the predominant isolate (87 percent) in
1987 to only 31 percent in 1992 (one year after the introduction of fluconazole). Also
noted were proportionate increases in the percentages of C. glabrata, C. parapsilosis, and
C. tropicalis isolates, which were generally less sensitive to fluconazole. Use of flucona-
zole for prophylaxis in bone marrow transplantation patients [12] was noted to be associ-
ated with an approximately twofold higher colonization rate and approximately sevenfold
higher infection rate of C. krusei, which is natively resistant to fluconazole.
Candida species are normal commensals in the human gut, respiratory, and female
genital tracts. The principal defenses against invasive infection are normal bacterial flora,
intact integument and, if this is breached, blood and tissue phagocytes [10]. The roles of
humoral immunity andT-lymphocytes are less well characterized. Antibodies are made to
several Candida antigens, but their functional significance is unclear. The importance of
T-cell function is suggested by the presence ofdelayed-type hypersensitivity to Candida
antigens in most adults with normal immune systems, as well as the increased vulnerabil-
ity of persons with HIV disease to mucocutaneous Candida infections.
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The most important risk factors associated with candidemia and deep Candida infec-
tions are summarized in Table 2. In general, most of these conditions involve either
breaching of integument or impaired phagocytic function. Immunosuppression, such as
that associated with organ or bone marrow transplantation, is associated with extremely
high risk. Some studies suggest a predilection for C. tropicalis infections in patients
undergoing treatment for leukemia and lymphoma [13, 14], though this has not been as
apparent in more recent series [9]. As discussed above, use ofbroad spectrum antibiotics,
central venous catheters, and parenteral hyperalimentation also appear to predispose to
candidemia. Parenteral hyperalimentation fluids support growth of Candida species by
virtue of their high dextrose content. C. parapsilosis has been noted to have a particular
affinity for such high-dextrose solutions and outbreaks of C. parapsilosis fungemia have
been traced to contaminated fluids and laboratory equipment used in theirpreparation [14,
15].
In addition to hematologic malignancies and neutropenia, underlying illnesses asso-
ciated with an increase in Candida infections include human immunodeficiency virus
infection, diabetes mellitus, and chronic renal failure. HIV infection definitely does pre-
dispose to mucocutaneous candidiasis (oral thrush, esophageal, and vulvovaginal candidi-
asis), but disseminated candidiasis associated with HIV infection alone is relatively rare
[16]. Chronic renal failure predisposes to fungal peritonitis, primarily candidal, in patients
with indwelling peritoneal dialysis catheters [17].
Table 2. Risk factors for severe Candida infections.
Severe underlying disease








Other conditions and iatrogenic factors
intravenous drug use
central venous catheters
broad spectrum antibiotic use
systemic steroids, immunosuppressive and cytotoxic agents
parenteral hyperalimentation
trauma, bums
abdominal and thoracic surgery
CLINICAL MANIFESTATIONS
Once in the bloodstream, Candida produce a clinical picture which is indistinguish-
able from bacteremia, with fever, leukocytosis, and hypotension, and which may progress
to septic shock. In a series of 55 surgical patients with candidemia, 71 percent had a
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leukocytosis, 60 percent were febrile, and 29 percent were hypotensive [7]. From the
bloodstream the organism can disseminate to multiple organs, producing diffuse microab-
scesses. The skin, eye, kidney, and brain are most commonly affected, but myocardium,
heart valves, joints, and bone may be involved as well [18, 19].
Chronic disseminated candidiasis, also referred to as hepatosplenic candidiasis, is a
distinct clinical entity. It occurs primarily in cancer chemotherapy patients who are recov-
ering from neutropenia. Typically patients with this infection have right upper quadrant
abdominal pain and are persistently febrile after recovery from neutropenia despite broad
spectrum antibiotics [19].
DIAGNOSIS
Most Candida species grow well in routine vented or biphasic blood culture bottles
[20]. However, severe multiorgan infection can exist in the absence ofpositive blood cul-
tures. This makes definitive diagnosis of disseminated candidiasis difficult, and often
results in delay in the institution of therapy.
Telenti et al. [21] conducted a retrospective review of all cases of Candida-positive
blood cultures at their institution between 1985 and 1987 (172 episodes in 169 patients).
The authors classified each case either as a probable intravascular infection (defined as
having intravascular device present, positive peripheral blood cultures before removal of
device, catheter tip grew at least 15 colony-forming units (cfu), no other source identified;
patients with endocarditis included in this group), or extravascular infection (defined as
culture proven extravascular source and either no intravenous device present or tip grew
less than 15 colony-forming units). Of these, 39 percent of cases were classified as
intravascular, 42 percent as extravascular, and 17 percent as unidentified. Marked differ-
ences were observed in the mean colony counts for the intravascular vs. extravascular
groups (45 cfu vs. 1 cfu). It is important to note that patients in this study were included
on the basis of having a positive peripheral blood culture; therefore each case would be
expected to have some number ofcolony forming units on quantitative culture. The strik-
ing feature ofthese data is the extremely low colony count for nearly all the patients with
extravascular infections, as well as a significant number ofthose with intravascular infec-
tions (for 19 ofthe 172 episodes, 5 or fewercfu were noted on quantitative culture). These
observations suggest that there might be patients with similar infections and negative
blood cultures. This possibility is supported by the observations of Berenguer et al. [22].
In a retrospective review of 67 cases of autopsy-proven single-organ and multiorgan dis-
seminated candidiasis, these authors found that only 28 percent ofsingle-organ cases and
58 percent of multiorgan cases had any positive blood cultures, even though the median
number of blood cultures was 11 in the single-organ group and 17 in the disseminated
group.
The unreliability of culture-based diagnosis has led to substantial efforts to develop
other diagnostic methods. These have recently been reviewed elsewhere [23]. Numerous
serologic assays have been developed which are designed to detect circulating Candida
antigens. These include the cell wall polysaccharide mannan, a 48 kD cytoplasmic glyco-
protein antigen, and a heat-labile glycoprotein antigen. Another approach involves detec-
tion of sugar alcohol metabolites such as D-arabinitol by gas chromatography. Also, a
polymerase chain reaction assay was recently developed which detects conserved portions
of the Candida actin gene [24]. Other assays have been designed which detect antibodies
to major cytoplasmic protein antigens. However, no serologic or polymerase chain reac-
tion assay to date has been found to have sufficient sensitivity and specificity. Therefore
none ofthese tests has yet been developed for routine clinical use. Therefore, the decision
to treat patients for candidemia and/or disseminated candidiasis rests in large part upon
maintaining a high degree of suspicion, particularly in the susceptible host with one or
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more risk factors, and often must be undertaken empirically, without confirmatory data
from cultures or other tests.
TREATMENT
The currently available antifungal agents most often used to treat patients for docu-
mented candidemia and/or disseminated candidiasis include amphotericin B, fluconazole,
and 5-fluorocytosine. Ofthese, amphotericin B is the oldest, and although it has the great-
est potential toxicity, it also has the advantage of being the most well-known agent in
terms of efficacy in serious Candida infections.
Amphotericin B is a lipophilic polyene first isolated in 1956 from Streptomyces
nodosus. It acts by binding to ergosterol, a steroid crucial to fungal cell wall integrity,
causing leakage ofcellular contents and cell death. Conventional amphotericin B consists
of the drug complexed to sodium deoxycholate in order to improve water solubility. It is
available only in intravenous formulation for systemic use, as it is poorly absorbed though
the gastrointestinal tract. Cerebrospinal fluid penetration is poor [25, 26]. Amphotericin B
has a number of important adverse effects, the most common of which are nephrotoxici-
ty (secondary to renal vascular spasm, proximal and distal tubulardamage, and renal tubu-
lar acidosis) and anemia (secondary to direct suppression oferythropoesis and sometimes
thrombopoesis) [27]. Most species of Candida are susceptible, but both primary and sec-
ondary resistance are seen in C. lusitaniae and occasionally in other Candida species [28].
Lipid-associated amphotericin B preparations include liposomal amphotericin B,
amphotericin B colloidal dispersion, and amphotericin B lipid-complex. Rather than
deoxycholate, the lipid-associated preparations contain amphotericin B incorporated into
liposomes, complexed with cholesteryl sulfate, or with dimyristoyl phosphatidylcholine
and dimyristoyl phosphatidylglycerol. These agents have a wider therapeutic index than
conventional amphotericin B, allowing administration of higher cumulative doses with
minimum renal toxicity [29-32]. In addition, these agents are preferentially taken up by
the reticuloendothelial cells ofthe liver and spleen, offering a theoretical advantage in the
treatment of hepatosplenic canddiasis. Amphotericin B lipid complex, with dimyristoyl
phosphatidylcholine and dimyristoyl phosphatidylglycerol, was recently licensed for use
in the United States.
5-Fluorocytosine (5-FC) or flucytosine is a water-soluble pyrimidine. It is converted
to 5-fluorouracil (5-FU) by the enzyme cytosine deaminase in susceptible fungi. 5-FU in
turn is converted into 5-fluoro-2'-deoxyuridylic acid (FdUMP), which inhibits thymidy-
late synthtase and therefore inhibits DNA synthesis. Cytosine deaminase is not present in
human cells; therefore the conversion of 5-FC to 5-FU is confined to susceptible fungi
[33]. It is absorbed well orally and penetrates the cerebrospinal fluid well. Although the
majority of Candida species are initially susceptible, resistance develops readily; there-
fore flucytosine cannot be used as a single agent. It is used primarily in combination with
amphotericin B in serious candidal and cryptococcal infections which fail to respond to
amphotericin B alone. However, no evidence currently exists to suggest that the addition
of flucytosine provides any therapeutic advantage over amphotericin alone in the treat-
ment ofserious Candida infections. The combination ofthe two can in fact be quite harm-
ful, as both may cause bone marrow suppression [25]. 5-FU has been noted to be present
in human serum after the administration of 5-FC, possibly secondary to conversion by
intestinal microflora followed by gut reabsorbtion, and this is one mechanism that has
been put forth for the myelosuppressive effect ofthe drug [34]. However, a study of 5-FC
toxicity in patients withcryptococcal meningitis found thatpeak 5-FU levels were not pre-
dictive oftoxicity [35].
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Fluconazole is a water soluble triazole which was introduced in 1991. It selectively
inhibits the fungal cytochrome P-450 enzymes which catalyze the conversion oflanosterol
to ergosterol. Oral bioavailability is 85-90 percent, and CSF penetration is 80 percent in
the presence ofinflamed meninges [36]. It has a broad spectrum ofactivity including most
Candida species, but C. krusei is resistant, as well as Aspergillus species.
A comparison ofthe toxicities and adverse effects ofamphotericin B and fluconazole
is shown in Table 3. With the exception of hepatic necrosis, which is rare, the adverse
effects of fluconazole are relatively minor compared with those ofamphotericin B. Also,
the most common adverse effects of fluconazole (nausea, abdominal pain and headache)
occur with fairly low frequency (less than 2.5 percent) [37]. This contrasts with the fre-
quency of nephrotoxicity (nearly 100 percent) and hematologic toxicity (approximately
75 percent) observed with amphotericin B [27].
Table 3. Adverse effects ofamphotericin B and fluconazole.
Amphotericin B Fluconazole
thrombophlebitis nausea, vomiting, abdominal pain
chills, fever, aches rash (rarely exfoliative)
nausea/vomiting headache
hypotension elevated liver function tests
nephrotoxicity hepatic necrosis (rare)
hypokalemia
hypomagnesemia
suppression oferythro- and thrombopoesis
The more favorable toxicity profile of fluconazole makes it an attractive alternative
agent to amphotericin B. There are numerous reports in the literature which describe the
successful use of fluconazole in the treatment of oropharyngeal candidiasis, as well as
deep-seated Candida infection, including endocarditis [38], endophthalmitis [39],
osteomyelitis [40], andprostheticjoint infections [41]. However, there is apaucity ofstud-
ies which directly compare the efficacy of fluconazole with that of amphotericin B.
Amphotericin B therefore remains the treatment of choice for most sorts of serious
Candida infection.
One notable exception is in the treatment ofcandidemia in non-neutropenic patients.
A recent randomized trial [42] included 206 patients with culture-documented candidemia
withoutneutropenia ormajorimmunodeficiency (patients with hematologic malignancies,
acquired immunodeficiency syndrome, and organ transplantation were excluded) and who
had not received greater than 0.6 mg/kg ofamphotericin B or 400 mg offluconazole pre-
viously. All had fever, hypotension, or other signs of infection. Patients were randomly
assigned to receive either 0.5-0.6 mg/kg/day of amphotericin B or 400 mg/day of flu-
conazole. Therapy continued for 14 days after the resolution of clinical signs or 14 days
after the last positive blood culture, whichever period was longer. Therapy with flucona-
zole was discontinued ifthe serum alkaline phosphatase rose to greater than 1.5 times nor-
mal or baseline, or if serum transaminases exceeded three times normal or baseline;
amphotericin B was discontinued if serum creatinine became greater than 3.5 mg/dl.
Patients in either treatment group received approximately the same duration of therapy
(mean 17 days for fluconazole and 18 days for amphotericin B). Treatment wasjudged to
be successful in 79 percent of patients in the amphotericin B group and 70 percent of
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patients in the fluconazole group; the difference in success rates was not statistically sig-
nificant. However, rates of adverse effects were significantly higher for amphotericin B
than fluconazole. Amphotericin B caused renal failure in 37 percent of 103 patients and
hypokalemia in 10 percent, while the frequency of both of these effects was only 2 per-
cent among the 103 patients in the fluconazole group. The frequency of elevated liver
function tests, on the other hand, was 14 percent in the fluconazole group (not statistical-
ly significant) compared with 10 percent in the amphotericin B group.
This study offers evidence for the promise of fluconazole as an effective, safe thera-
peutic agent for the treatment ofsystemic Candida infections in non-neutropenic patients.
It has important limitations, however, which must be considered. First, the study popula-
tion was very carefully selected, excluding patients with the most common immunodefi-
ciency states which predispose to serious Candida infections. It was not specified whether
any patients were on systemic steroid therapy, so it is unclear whether fluconazole would
be equally effective to amphotericin B in patients taking such agents. Also, it is important
to note that the majority ofinfections in this study were caused by to C. albicans, and that
other species were not represented in sufficiently large numbers to allow for detection of
differences in the relative efficacy of the two antifungal agents.
The currently recommended first-line therapy for candidemia and disseminated
Candida infections in neutropenic and otherwise immunocompromised hosts is therefore
still amphotericin B, at a dose of 0.5-0.7 mg/kg/day, to be continued until fourteen days
after resolution of clinical symptoms and signs or after the last positive blood culture. In
non-neutropenic, non-immunosuppressed patients, fluconazole may be used as a first-line
agent, with the duration of therapy determined on the same basis. Fluconazole may also
be used as a second line agent in immunosuppressed patients who are unable to tolerate
the adverse effects ofamphotericin B. Any intravascular catheters should be removed and
completely changed if possible, as leaving catheters in prolongs the duration of can-
didemia [43]. Chronic disseminated or hepatosplenic candidiasis responds poorly to con-
ventional amphotericin B therapy [44, 45], butfluconazole is effective and is therefore the
first-line therapy for this infection [46-49]. Liposomal amphotericin B has also been found
to be effective in chronic disseminated candidiasis [50].
SUMMARY
Systemic Candida infections pose many and increasingly frequent challenges in
terms ofdiagnosis and treatment. Timely institution oftreatment for these potentially life-
threatening infections relies upon maintaining a high degree of clinical suspicion in
patients with one or more risk factors, particularly those who remain ill or febrile despite
broad spectrum antibacterial agents. Blood cultures are not a sensitive means ofdetecting
candidemia and disseminated candidiasis, and therefore negative blood cultures should
not preclude empiric therapy for the at-risk patient in the appropriate clinical situation.
Finally, although the toxicity of amphotericin B is problematic, it is still considered the
first-line therapy for most systemic candidal infections, with two exceptions being can-
didemia in non-immunocompromised hosts and chronic disseminated candidiasis.
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